Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rao V Kalla

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Purinergic Signalling|June 24, 2008
Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidatesRao V Kalla, Jeff Zablocki
Handbook of Experimental Pharmacology|July 30, 2009
Recent developments in A2B adenosine receptor ligandsRao V Kalla, Jeff Zablocki, Mojgan Aghazadeh Tabrizi, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2008
Selective, high affinity A(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthinesRao V Kalla, Elfatih Elzein, Thao Perry, et al.
Journal of Medicinal Chemistry|March 7, 2008
Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseasesElfatih Elzein, Rao V Kalla, Xiaofen Li, et al.
Journal of Medicinal Chemistry|June 9, 2006
Novel 1,3-disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A2B adenosine receptor antagonistsRao V Kalla, Elfatih Elzein, Thao Perry, et al.
Journal of Medicinal Chemistry|August 19, 2023
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green MonkeysRichard L Mackman, Rao V Kalla, Darius Babusis, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Purinergic Signalling|June 24, 2008
Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidatesRao V Kalla, Jeff Zablocki
Handbook of Experimental Pharmacology|July 30, 2009
Recent developments in A2B adenosine receptor ligandsRao V Kalla, Jeff Zablocki, Mojgan Aghazadeh Tabrizi, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2008
Selective, high affinity A(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthinesRao V Kalla, Elfatih Elzein, Thao Perry, et al.
Journal of Medicinal Chemistry|March 7, 2008
Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseasesElfatih Elzein, Rao V Kalla, Xiaofen Li, et al.
Journal of Medicinal Chemistry|June 9, 2006
Novel 1,3-disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A2B adenosine receptor antagonistsRao V Kalla, Elfatih Elzein, Thao Perry, et al.
Journal of Medicinal Chemistry|August 19, 2023
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green MonkeysRichard L Mackman, Rao V Kalla, Darius Babusis, et al.
Pageof 1